Polio

SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil

Retrieved on: 
Thursday, July 14, 2022
COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, COVID-19, Influenza A virus subtype H1N1, Program, Pulmonology, Vaccine, H5N1, Infection, HFMD, SBP, WHO, Vaccination, Company, Hepatitis A, R, Mumps, Foot-and-mouth disease virus, Ageing, Brazilian Association of Investigative Journalism, Minor, SBI, Chickenpox, Instituto Butantan, Sinovac Biotech, Research, Association, CoronaVac, EV71, Streptococcus, To Brazil!, NASDAQ, Polio, Pharmaceutical industry, Brazilian Health Regulatory Agency, COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science

This authorization was given under comprehensive evaluations based on analysis results from all available data on the vaccine and its use in children.

Key Points: 
  • This authorization was given under comprehensive evaluations based on analysis results from all available data on the vaccine and its use in children.
  • To assist Anvisa in evaluating the vaccine, the experts from the above institutions had access to technical materials and research data on the vaccine.
  • CoronaVac has been authorized for emergency use for adults in Brazil since January 17, 2021.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China

Retrieved on: 
Monday, July 4, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Department, Pharmacy and Poisons Board, Pharmacy, Influenza A virus subtype H1N1, School, Admission, CEO, RNA transfection, Adult, Research, GHK, Trial of the century, Polio, Li Ka Shing Faculty of Medicine, Wong Chuk Hang, Infection, COVID-19, Immunization, Â, Sinovac Biotech, Department of Medicine – University of Pamplona, HKU, Omicron, School of Clinical Medicine, University of Cambridge, LKS, Viral hepatitis, Asia-Pacific, Campus Biotech, IHH Healthcare, Poison, Clinical trial, NWS Holdings, University, IRB, Virus, Pyaar Tune Kya Kiya (TV series), Animal, Vaccine, Chickenpox, Safety, University of Hong Kong, Vaccination, EV71, Immunity, Faculty, Mumps, Bed, Multimedia, International business, Volunteering, Pharmaceutical industry, Medicine, Gleneagles Hospital

This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles.

Key Points: 
  • This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles.
  • The University of Hong Kong Clinical Trials Centre (HKU-CTC) is a one-stop clinical research management platform dedicated to facilitating the professional conduct of clinical research projects under HKUMed.
  • As Hong Kongs top-notch private teaching hospital, Gleneagles also contributes to the training and development of healthcare professionals and advancement of clinical research.
  • Gleneagles is a joint venture between IHH Healthcare and NWS Holdings Limited, with The University of Hong Kong as its exclusive clinical partner.

SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa

Retrieved on: 
Saturday, June 25, 2022
Biotechnology, Pharmaceutical, Health, COVID-19, Influenza A virus subtype H1N1, Research, SAHPRA, Chinese government award for outstanding self finance students abroad, Polio, COVID-19, South African Health Products Regulatory Authority, Company, Hepatitis A, Hepatitis, Ageing, Infection, H5N1, Streptococcus, Sinovac Biotech, Risk management, Foot-and-mouth disease virus, NASDAQ, Vaccine, HFMD, Chickenpox, Safety, Mumps, EV71, WHO, Pharmaceutical industry

All the evidence suggested that the SINOVAC COVID-19 vaccine was safe and effective.

Key Points: 
  • All the evidence suggested that the SINOVAC COVID-19 vaccine was safe and effective.
  • SINOVAC COVID-19 vaccine has been available in more than 60 countries, with a total supply of almost 2.9 billion doses.
  • Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
  • SINOVAC has been continually dedicating itself to new vaccine research and development, with more combination vaccine products in the pipeline, and constantly exploring opportunities in the international market.

SINOVAC Polio Vaccine Prequalified by WHO

Retrieved on: 
Thursday, June 9, 2022
Infectious Diseases, Biotechnology, Pharmaceutical, Health, GPEI, World Health Organization, UN, Polio, OPV, Global Polio Eradication Initiative, Research, Food, Immunization, Infection, Influenza A virus subtype H1N1, United Nations, Poliovirus, VAPP, Polio eradication, Sinovac Biotech, Mouth, Environment, Hepatitis A, Pain, WHO, Fever, Chickenpox, Motor neuron, Vaccine, Feces, Campus Biotech, Saliva, COVID-19, NASDAQ, Prevalence, CoronaVac, Water, Public health, Mumps, Profile, EV71, World

The vaccine will be available for United Nations (UN) agencies to purchase to support the global polio endgame strategy.

Key Points: 
  • The vaccine will be available for United Nations (UN) agencies to purchase to support the global polio endgame strategy.
  • The vaccine can be used sequentially with oral polio attenuated live vaccine (OPV).
  • With the impact of the global COVID-19 pandemic, countries where wild polio strains still exist have experienced an increasing prevalence of polio cases.
  • SINOVAC has been continually dedicating itself to new vaccine research and development, with more combined and new technology vaccine products in the pipeline.

Komodo Health Appoints Dr. Aswin Chandrakantan as Chief Operating Officer

Retrieved on: 
Tuesday, May 24, 2022
Venture Capital, Software, Health, Data Management, Professional Services, Technology, Clinical Trials, Other Technology, Komodo, The College of New Jersey, Polio, McKinsey & Company, Disease, COO, CRC, Dentistry, Health, List of life sciences, Decision-making, BS, Algorithm, Culture, Partnership, Â, Commercial, University of Medicine and Dentistry of New Jersey, University, Technology, College, Organization, Gaps, Internationalized domain name, Machine learning, Rutgers University, Growth, MD, Medical device, Management, Customer

Komodo Health today announced that Dr. Aswin Chandrakantan has been appointed as the companys first Chief Operating Officer, effective immediately.

Key Points: 
  • Komodo Health today announced that Dr. Aswin Chandrakantan has been appointed as the companys first Chief Operating Officer, effective immediately.
  • Dr. Chandrakantan will also retain his responsibilities as Komodos Chief Medical Officer.
  • Prior to Komodo Health, Dr. Chandrakantan was a senior leader in Googles Global Product Operations and Strategy.
  • Komodo Health appoints Dr. Aswin Chandrakantan as the companys first Chief Operating Officer.

Sabin Vaccine Institute Receives up to $6.3 Million from CEPI for Dose-Optimizing COVID-19 Vaccine Clinical Trial

Retrieved on: 
Tuesday, May 17, 2022
Polio, CEPI, Public health, Coalition, Sabin Vaccine Institute, Coalition for Epidemic Preparedness Innovations, Yellow fever vaccine, Vaccine, PATH, Epidemic, Yellow fever, Clinical trial, COVID-19, Research, Vaccination, Partnership, Time, Safety, Immunization, Pfizer–BioNTech COVID-19 vaccine, CEO, AstraZeneca, GLOBE

This research has the potential to have the biggest impact in the places that need it the most, said Amy Finan, CEO of the Sabin Vaccine Institute.

Key Points: 
  • This research has the potential to have the biggest impact in the places that need it the most, said Amy Finan, CEO of the Sabin Vaccine Institute.
  • Just 1 in 6 people, 17.4%, have received a COVID-19 vaccine in low-income countries, compared to 72% in high income countries.
  • That was Dr. Sabins goal during his lifetime, and its the goal now of the Sabin Vaccine Institute and this research.
  • Our new partnership with Sabin Vaccine Institute and PATH will provide critical insights into this fractional dose approach.

SINOVAC Updates the Status Under Holding Foreign Companies Accountable Act

Retrieved on: 
Friday, May 6, 2022
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Mumps, COVID-19, Forward-looking statement, Hepatitis, Chickenpox, NASDAQ, PCAOB, Sinovac Biotech, Company, EV71, Annual report, Holding, WHO, Program, Holding Foreign Companies Accountable Act, Private Securities Litigation Reform Act, Form 20-F, Chinese government award for outstanding self finance students abroad, Vaccine, Hepatitis A, Influenza A virus subtype H1N1, Polio, U.S. Securities and Exchange Commission, SEC, Infection, Terminology, H5N1, EUL, Research

Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, is aware that the Company has been identified by the United States Securities and Exchange Commission (SEC) under the Holding Foreign Companies Accountable Act of the United States (the HFCAA) on May 4, 2022.

Key Points: 
  • Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, is aware that the Company has been identified by the United States Securities and Exchange Commission (SEC) under the Holding Foreign Companies Accountable Act of the United States (the HFCAA) on May 4, 2022.
  • Similar to other companies that have also been identified, SINOVAC notes such identification resulted from the Companys filing of its annual report on Form 20-F for the fiscal year ended December 31, 2021.
  • SINOVAC will continue to closely monitor developments and explore options in relation to the HFCAA.
  • Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases.

Global Travel Vaccines Market Forecast Report 2021-2028: Travel Mandates & Regulations, Never-ending Demand for Vaccines, and Awareness Regarding Vaccines - ResearchAndMarkets.com

Retrieved on: 
Friday, April 22, 2022
Health, Infectious Diseases, Other Travel, Travel, Pharmaceutical, Biotechnology, Pfizer, Hepatitis, Travel, Awareness, GlaxoSmithKline, COVID-19, Merck & Co., Yellow fever, JE, Incidence, DPT, CAGR, Fever Dream, Rubella, Valneva SE, Novartis, Bharat Biotech, Patient, Cholera, Merck, Growth, Infection, Friends, Vaccination, Person, Hepatitis A, Application, Hepatitis B, Vaccine, Rabies, Emergent, Polio, Inactivated vaccine, Immunization, Shingles, Emergent BioSolutions, Pharmaceutical industry, Sanofi

The "Travel Vaccines Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product and Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Travel Vaccines Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product and Application" report has been added to ResearchAndMarkets.com's offering.
  • However, the high cost of travel vaccines hinders the travel vaccines market's growth.
  • The report highlights the key factors driving the market and prominent players with their developments in the market.
  • These companies have taken various steps and driven innovations in the travel vaccines market, leading to the market's growth.

Press Release: Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines

Retrieved on: 
Thursday, March 31, 2022
Trypanosomiasis, SNY, Research, SEC, Medicine, MUFG, Goal, Securities Act of 1933, Barclays, Note, Intellectual property, AMF, Sale, Social responsibility, Achievement, Polio, Person, EMA, Relevance (Person of Interest), Science, Order, Directive 2014/65/EU, Morgan Stanley, EEA, NASDAQ, Investment, Forward-looking statement, Degenerative disease, RBC Capital Markets, Annual report, Financial Services and Markets Act 2000, Article, ISS, SAN, FDA, Patient, Form 20-F, United Kingdom, Financial services, European Economic Area, Urban economics, Communication, Party, COVID-19, KID, EUR, Finance, Workplace, Infection, Pharmaceutical industry, Security (finance), Risk management, Medical device, Private investigator, Sanofi, EU

Sanofi successfully priced yesterday, March 30, 2022, its offering of a dual-tranche EUR 1.5 billion of notes (the Notes).

Key Points: 
  • Sanofi successfully priced yesterday, March 30, 2022, its offering of a dual-tranche EUR 1.5 billion of notes (the Notes).
  • To become an issuer of sustainable finance instruments, Sanofi has established a dedicated Sustainability-Linked Bond Framework , designed as a living document to enable future bond issues in a sustainability-linked format.
  • The Sustainability-Linked Bond Framework is aligned with ICMAs Sustainability-Linked Bond Principles (2020) and has received a Second Party Opinion from ISS ESG.
  • Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

MaxLinear Announces Intelligent Point of Load Solutions at APEC 2022

Retrieved on: 
Tuesday, March 22, 2022
Data Management, Semiconductor, Technology, Mobile, Wireless, Software, Networks, Hardware, Polio, CAGR, Bio-FET, NASDAQ, DVS, QFN, Power Management Bus, Forward-looking statement, APEC, Multimedia, 20A, MaxLinear, Conference, PCI Express, Lists of disasters, Dynamic voltage scaling, 12A, Wireless Home Digital Interface, Power semiconductor device, Intelligence, Industry, COVID-19, MXL, U.S. Securities and Exchange Commission, Mexicali, 6A, Efficiency, Annual report, Power management, Video game console, Renewable energy

MaxLinear Inc. (NASDAQ: MXL) announced a new line of Intelligent POLs (iPOLs) supporting server, data center, networking, and wireless communications applications.

Key Points: 
  • MaxLinear Inc. (NASDAQ: MXL) announced a new line of Intelligent POLs (iPOLs) supporting server, data center, networking, and wireless communications applications.
  • Edge-located servers are the fastest growing market segment within data centers and are forecast to grow five-fold from 2022 to 2025.
  • MaxLinear will showcase the MxL76xxP family at the APEC Conference in Houston, Texas, on March 21 through 24, Booth #1606.
  • MxL and the MaxLinear logo are trademarks of MaxLinear, Inc. Other trademarks appearing herein are the property of their respective owners.